Trial · NCT03298984
Adverse events660
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
81 to 100 of 660
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dyspepsia | Gastrointestinal disorders | Alvocidib 20/30 mg/m2 (N=3) | 1 | 3 | |
| other | Dyspepsia | Gastrointestinal disorders | Alvocidib 30/40 mg/m2 (N=3) | 0 | 3 | |
| other | Dyspepsia | Gastrointestinal disorders | Alvocidib 30/50 mg/m2 (N=3) | 0 | 3 | |
| other | Dyspepsia | Gastrointestinal disorders | Alvocidib 30/60 mg/m2 (N=23) | 6 | 23 | |
| other | Constipation | Gastrointestinal disorders | Alvocidib 20/30 mg/m2 (N=3) | 0 | 3 | |
| other | Constipation | Gastrointestinal disorders | Alvocidib 30/40 mg/m2 (N=3) | 2 | 3 | |
| other | Constipation | Gastrointestinal disorders | Alvocidib 30/50 mg/m2 (N=3) | 3 | 3 | |
| other | Constipation | Gastrointestinal disorders | Alvocidib 30/60 mg/m2 (N=23) | 5 | 23 | |
| other | Dry mouth | Gastrointestinal disorders | Alvocidib 20/30 mg/m2 (N=3) | 0 | 3 | |
| other | Dry mouth | Gastrointestinal disorders | Alvocidib 30/40 mg/m2 (N=3) | 0 | 3 | |
| other | Dry mouth | Gastrointestinal disorders | Alvocidib 30/50 mg/m2 (N=3) | 1 | 3 | |
| other | Dry mouth | Gastrointestinal disorders | Alvocidib 30/60 mg/m2 (N=23) | 5 | 23 | |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | Alvocidib 20/30 mg/m2 (N=3) | 0 | 3 | |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | Alvocidib 30/40 mg/m2 (N=3) | 0 | 3 | |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | Alvocidib 30/50 mg/m2 (N=3) | 1 | 3 | |
| other | Gastrooesophageal reflux disease | Gastrointestinal disorders | Alvocidib 30/60 mg/m2 (N=23) | 5 | 23 | |
| other | Haemorrhoids | Gastrointestinal disorders | Alvocidib 20/30 mg/m2 (N=3) | 0 | 3 | |
| other | Haemorrhoids | Gastrointestinal disorders | Alvocidib 30/40 mg/m2 (N=3) | 1 | 3 | |
| other | Haemorrhoids | Gastrointestinal disorders | Alvocidib 30/50 mg/m2 (N=3) | 1 | 3 | |
| other | Haemorrhoids | Gastrointestinal disorders | Alvocidib 30/60 mg/m2 (N=23) | 5 | 23 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03298984/events?page=5